Skye Bioscience Statistics Share Statistics Skye Bioscience has 30.99M
shares outstanding. The number of shares has increased by 2.14%
in one year.
Shares Outstanding 30.99M Shares Change (YoY) 2.14% Shares Change (QoQ) 0.01% Owned by Institutions (%) 51.16% Shares Floating 18.62M Failed to Deliver (FTD) Shares 5,375 FTD / Avg. Volume 1.23%
Short Selling Information The latest short interest is 2.75M, so 8.86% of the outstanding
shares have been sold short.
Short Interest 2.75M Short % of Shares Out 8.86% Short % of Float 13.31% Short Ratio (days to cover) 6.89
Valuation Ratios The PE ratio is -3.89 and the forward
PE ratio is -3.25.
Skye Bioscience's PEG ratio is
0.04.
PE Ratio -3.89 Forward PE -3.25 PS Ratio 0 Forward PS n/a PB Ratio 1.52 P/FCF Ratio -3.85 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Skye Bioscience.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 16.32,
with a Debt / Equity ratio of 0.01.
Current Ratio 16.32 Quick Ratio 16.32 Debt / Equity 0.01 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage -48.61
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.66M Employee Count 16 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 10.07K Effective Tax Rate -0.04%
Stock Price Statistics The stock price has increased by 33.8% in the
last 52 weeks. The beta is 2.35, so Skye Bioscience's
price volatility has been higher than the market average.
Beta 2.35 52-Week Price Change 33.8% 50-Day Moving Average 3.74 200-Day Moving Average 2.89 Relative Strength Index (RSI) 68.45 Average Volume (20 Days) 437,454
Income Statement
Revenue n/a Gross Profit -298.64K Operating Income -36.43M Net Income -26.57M EBITDA -25.51M EBIT -25.81M Earnings Per Share (EPS) -0.73
Full Income Statement Balance Sheet The company has 68.42M in cash and 455.59K in
debt, giving a net cash position of 67.96M.
Cash & Cash Equivalents 68.42M Total Debt 455.59K Net Cash 67.96M Retained Earnings -130.95M Total Assets 52.16M Working Capital 42.27M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -25.24M
and capital expenditures -1.6M, giving a free cash flow of -26.84M.
Operating Cash Flow -25.24M Capital Expenditures -1.6M Free Cash Flow -26.84M FCF Per Share -0.74
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields SKYE does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SKYE is $15,
which is 215.8% higher than the current price. The consensus rating is "Buy".
Price Target $15 Price Target Difference 215.8% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 8, 2023. It was a
backward
split with a ratio of 1:250.
Last Split Date Sep 8, 2023 Split Type backward Split Ratio 1:250
Scores Altman Z-Score 2.23 Piotroski F-Score 2
